Provided by Tiger Trade Technology Pte. Ltd.

ArriVent BioPharma

31.03
+0.52001.70%
Post-market: 31.030.00000.00%16:10 EDT
Volume:465.36K
Turnover:14.35M
Market Cap:1.53B
PE:-8.39
High:31.39
Open:30.58
Low:30.22
Close:30.51
52wk High:35.83
52wk Low:17.00
Shares:49.31M
Float Shares:32.11M
Volume Ratio:1.29
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6975
EPS(LYR):-4.3239
ROE:-53.25%
ROA:-33.11%
PB:4.17
PE(LYR):-7.18

Loading ...

Jun 20, 2025

Major Issues Report

Form 8-K - Current report
May 12, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2025

Major Issues Report

Form 8-K - Current report
Apr 28, 2025

Major Issues Report

Form 8-K - Current report
Mar 13, 2025

Major Issues Report

Form 8-K - Current report
Mar 03, 2025

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 03, 2025

Major Issues Report

Form 8-K - Current report
Mar 03, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jan 22, 2025

Major Issues Report

Form 8-K - Current report
Dec 04, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Nov 14, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2024

Major Issues Report

Form 8-K - Current report
Nov 12, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Oct 11, 2024

Beneficial Ownership Change

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Sep 09, 2024

Major Issues Report

Form 8-K - Current report
Aug 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 15, 2024

Major Issues Report

Form 8-K - Current report
Jul 09, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]
Jul 09, 2024

Major Issues Report

Form 8-K/A - Current report: [Amend]